Dendreon Corp fka DNDNQ

[walldiver]

I noticed on Page 4 or 5 of the new guidelines that data from a trial for a different stage of the targeted disease can be used to support approval...hmmm...I know it's a long shot, but it would be interesting to see if they unblind PROTECT again in Q4, and look specifically at the time to distant metastases endpoint.

Edit: of course, this assumes that the agency isn't just paying lip service to its own new guidelines.